Combination of alfa blocker with low dose tadalafil in benign prostatic hyperplasia with erecticle dysfunction management
Abstract
Objective: To study the combination therapy with daily low dose tadalafil (5mg) and alpha blockers for the treatment of BPHLUTS and Erecticle dysfunction (ED). Materials and Methods: The medical records of 168 patients who had medical management for symptomatic BPH/LUTS with or without ED from January 2010 to December 2013 were reviewed retrospectively. All patients were divided into 2 groups. Group1(n: 74) included patients received a single daily dose of tamsulosin 0.4mg or alfuzosin 10mg . Group-2 (n:75) patients with LUTS and BPH who were previously managed with alpha blockers (tamsulosin 0.4mg or alfuzosin 10mg) were included in our study by addition of 5mg phosphodiesterase type 5 inhibitor (tadalafil), which has been reported to be useful in the management of BPH/LUTS and ED. We analysed the International Prostate Symptom Score (IPSS), IIEF Score, BPH Impact Index (BII) and Quality of Life (QoL). Results: Before the inclusion of tadalafil patients exclusively on alpha blockers had a mean IPSS score of 21.51 ± 2.89). IPSS improved to a mean of 11.34 ± 1.56 ( p
Read the paper
Related studies
- Erectile dysfunction
- Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit
- Alpha1-adrenoceptor subtypes and lower urinary tract symptoms
- Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets
- Chronic bladder ischemia and oxidative stress: New pharmacotherapeutic targets for lower urinary tract symptoms
- The role of prostate inflammation and fibrosis in lower urinary tract symptoms
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.